91ɫƵ

header-logo
GettyImages-609179959-hero

Blood and Marrow Transplant Program (BMT) and Cellular Therapy Program at the 91ɫƵ

Hematopoietic stem cell transplantation (blood and bone marrow stem cell transplantation) has proven results in several cancers of the blood and blood forming organs, marrow failure and immune deficiency states. In some instances it can cure, in other instances prolong life or improve the quality of life. Diseases such as leukemia and lymphoma that were considered untreatable even a generation ago are now increasingly treated with curative intent with this technique.

Sophisticated research facilities and advanced laboratories are necessary to bring the true benefits of transplantation to patients in need. 91ɫƵ with its close affiliation with the International Bone Marrow Transplant Registry and the Versiti Blood Center of Wisconsin, using the excellent treatment facilities of Froedtert Hospital and Children's Wisconsin, is able to bring to patients in need state of the art treatments. The research arm of 91ɫƵ is contributing to advancing the state of the art in cancer therapy and in the application of stem cell and gene therapy techniques to treat new diseases such as multiple sclerosis, lupus, and rheumatoid arthritis. These advanced techniques require the sophisticated facilities and advanced laboratories and expertise that combine research with treatment of patient diseases.
all
BMT Research
91ɫƵ is also one of the leading centers worldwide for research into blood and marrow transplantation. The Medical College is home to the Center for International Blood and Marrow Transplant Research (CIBMTR). The CIBMTR formed in 2004 brings together two major organizations in the field of blood and marrow transplant research: the National Marrow Donor Program® and the 91ɫƵ's International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry. The IBMTR has tracked the outcomes of transplants and conducted research into transplantation since 1972. The CIBMTR (CIBMTR) has also established the Stem Cell Therapeutic Outcomes Database (SCTOD) for the C.W. Bill Young Cell Transplantation Program (administered by the United States Health Resources and Services Administration (HRSA)).

The CIBMTR also facilitates and coordinates the Blood and Marrow Transplant (BMT) Clinical Trials Network (CTN). The CTN, established in October 2001 conducts large multi-institutional clinical trials in the field of hematopoietic stem cell transplantation. These trials address cutting edge issues in hematopoietic stem cell transplantation (HSCT), increasing the understanding of treatment approaches as well as developing novel ideas in the field. Dr. Mary M. Horowitz, a practicing transplant physician within the 91ɫƵ BMT program. is the Scientific Director of the CIBMTR and coordinates the Bone Marrow Transplant Clinical Trials Network.
91ɫƵ Transplant Program
91ɫƵ has pioneered clinical hematopoietic stem cell transplantation as well as research in this field. The 91ɫƵ/Froedtert Hospital Blood and Marrow Transplant (BMT) Program and Children's Wisconsin offer autologous, allogeneic, unrelated and mismatched and cord blood transplants. The combined adult and pediatric Blood and Marrow Transplant Program is the largest in the state and has performed transplants for over 35 years. Froedtert & the 91ɫƵ adult program has performed more than 1,000 bone marrow transplants here since 1980. In addition to patients with leukemia, lymphoma, multiple myeloma and solid-tumor cancers, patients with non-malignant blood disorders such as genetic anemias, immune deficiencies and sickle cell anemia, and autoimmune disorders such as multiple sclerosis have been treated over the years. The 91ɫƵ program is accredited by the Foundation for Accreditation of Hematopoietic Cell Therapy and is also approved by/affiliated with the National Marrow Donor Program, the Eastern Cooperative Oncology Group and the Children's Cancer Group.

The goals of the 91ɫƵ blood and marrow transplant programs are to save lives by applying state of the art technology to diseases in which Blood and marrow transplantation has demonstrated effectiveness, to extend the benefits of these treatments into new diseases where before little hope existed, and to improve therapies using genetic and immune manipulations and other targeted approaches that have higher success rates with fewer adverse side effects or complications.

91ɫƵ Transplant Team
The clinical program boasts the expertise of a team of internationally renowned transplant physicians who are involved in the leading the effort in making transplants safer and more effective. The program functions as a well integrated team so that the collective expertise of all the physicians is available for the individual patient in addition to that of their primary BMT physician. A dedicated team on exemplary middle level practitioners (Physician Assistants and Nurse Practitioners) trained in transplantation support the physician team.

Blood and Marrow Transplant (BMT) and Cellular Therapy Program

headshot

Sameem Abedin, MD

Associate Professor

headshot

Michael Deininger, MD, PhD

Professor of Medicine

headshot

Binod Dhakal, MD

Associate Professor

headshot

Anita D'Souza, MD

Associate Chief, Research, Division of Hematology/Oncology; Professor of Medicine

headshot

Areyl D. Goff, APNP

APP Hybrid

headshot

Mary M. Horowitz, MD, MS

Professor and Deputy Cancer Center Director; Robert A. Uihlein, Jr. Chair in Hematologic Research; Associate Director of Genomics; Scientific Director Emeritus, CIBMTR

headshot

Samantha Jaglowski, MD

Professor; Sr. Scientific Director, CIBMTR

headshot

Meera Mohan, MD, MS, FACP

Assistant Professor

headshot

Julie Pruett, APNP

APP Hybrid

headshot

James D. Rizzo, MD

Professor

headshot

Lyndsey Runaas, MD

Assistant Professor

headshot

Wael Saber, MD, MS

Professor

headshot

Nirav N. Shah, MD

Associate Professor

headshot

Bronwen E Shaw, MD, PhD

Professor; Scientific Director CIBMTR

headshot

Katie Zellner, PA-C

Physician Assistant